Business, energy, technology, markets and global industry news from Business News Today

HER2

PharmaDeviceNews HER2
Bispecific T-cell engagers originally developed for blood cancers are being repurposed to eliminate pathogenic B cells and plasma cells in severe autoimmune diseases, raising the possibility of CAR-T-like immune reset without the complexity of individualized cell manufacturing. Representative image.
Pharma & Biotech

World ADC 2026 highlights Invenra’s approach to HER2 and HER3 targeting

Invenra launches 52 Views of Cancer and expands trispecific ADC research targeting HER2 and HER3. See the science and development challenges.

Read More
Representative image: Gastric cancer imaging and biomarker analysis illustrate ALX Oncology’s evorpacept results in HER2-positive, CD47-high tumors from the ASPEN-06 study.
Pharma & Biotech

Evorpacept biomarker signal deepens in HER2-positive gastric cancer as ALX Oncology shifts focus

ALX Oncology’s evorpacept raises response to 63.6% in a HER2-retained, CD47-high gastric cancer subgroup, supporting biomarker-led development.

Read More
Representative image: Clinicians review lung cancer genomic testing data and blood-based diagnostic results, reflecting Guardant Health’s Guardant360 CDx FDA approval as a companion diagnostic for HERNEXEOS in HER2-mutant advanced non-small cell lung cancer.
Medical Devices & Diagnostics

How Guardant360 CDx approval supports Boehringer Ingelheim’s HERNEXEOS launch strategy

Find out how Guardant360 CDx approval could expand liquid biopsy use in HER2-mutant advanced lung cancer treatment selection.

Read More
Pharma & Biotech

How Celltrion’s HER2–CD3 bispecific could compete in the T-cell engager arena

Celltrion is going all-in on oncology biologics with ADCs, msAbs, and U.S. biomanufacturing scale-up. Find out what this shift means for global competition.

Read More